Product
Cabiralizumab
Aliases
BMS-986227, FPA008
6 clinical trials
7 indications
Indication
Advanced CancerIndication
Pancreatic CancerIndication
Triple-Negative Breast CancerIndication
MelanomaIndication
Lung CancerIndication
Renal Cell CarcinomaIndication
CancerClinical trial
ADaptiVe Biomarker Trial That InformS Evolution of TherapyStatus: Completed, Estimated PCD: 2021-03-31
Clinical trial
A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination With Nivolumab (BMS-936558) With and Without Chemotherapy in Patients With Advanced Pancreatic CancerStatus: Completed, Estimated PCD: 2023-06-01
Clinical trial
Phase Ib/II Study to Evaluate Safety and Tolerability of Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2023-03-20
Clinical trial
A Phase I/Ib Study of APX005M in Combination With Nivolumab and Cabiralizumab in Patients With Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma Whose Disease Has Progressed on Anti-PD- 1/PD-L1 TherapyStatus: Active (not recruiting), Estimated PCD: 2022-01-05
Clinical trial
Open Label Randomized Phase II Trial of Nivolumab + Cabiralizumab (BMS-986227, FPA008) + Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial).Status: , Estimated PCD: 2023-12-01
Clinical trial
Platform Phase 1 Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Immuno-oncology Agents for the Treatment of Multiple Metastases in Advanced Solid TumorsStatus: Completed, Estimated PCD: 2020-02-29